GeneDx Holdings Corp SEC Filings

GeneDx Holdings Corp. appointed Mark Gardner as President, effective June 15, 2026. He will oversee the company’s lab and commercial operations, report to CEO Katherine Stueland, and join the executive leadership team, while Bryan Dechairo shifts to a role leading product, technology and innovation initiatives.

Gardner previously led molecular genomics and oncology at Quest Diagnostics and held senior roles at Corza Medical, OmniSeq and Thermo Fisher Scientific. His employment agreement includes a $530,000 annual base salary, a target annual bonus equal to 65% of base salary, and $2,000,000 in restricted stock units vesting over four years, along with severance and change‑in‑control protections.

GeneDx Holdings Corp. chief financial officer Kevin Feeley reported RSU vesting and a related tax sale of common stock. On June 9, 2026, restricted stock units converted into 2,462 shares of Class A Common Stock for no cash consideration. On the same date, he sold 1,266 shares of Class A Common Stock at $53.77 per share in an open-market transaction to cover tax withholding obligations, described as a non-discretionary “sell to cover” event. After these transactions, he beneficially owned 36,486 shares of Class A Common Stock, as well as RSUs representing up to 89,240 additional shares and options to purchase up to 25,906 shares, which vest according to their terms. The RSUs vest in 6.25% quarterly installments, contingent on continued service.

GeneDx Holdings CEO Katherine Stueland exercised restricted stock units that converted into 6,546 shares of Class A Common Stock and sold 3,639 shares at about $53.77 per share. The sale was a “sell to cover” transaction to satisfy tax withholding obligations and was not discretionary. After these transactions, she beneficially owned 96,123 shares of common stock, RSUs for up to 324,275 additional shares, and options to purchase up to 107,610 shares that vest over time.

GeneDx Holdings Corp. reported an insider-related increase in holdings by entities associated with Casdin Capital. Casdin Partners Master Fund, L.P. made open-market purchases of 150,000 Class A common shares at $56.4449 per share on June 4, 2026 and 50,000 shares at $52.8566 per share on June 5, 2026, totaling 200,000 shares. After these trades, the Master Fund held 3,707,164 shares indirectly. Additional positions as of June 4, 2026 included 333,144 shares owned by the Master Fund, 19,247 shares owned by the GP entity, and 20,517 shares owned directly by Eli Casdin, each as separate holdings.

GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and a tax-related share sale. On June 1, 2026, 717 RSUs converted into the same number of Class A Common shares for no cash cost, reflecting vesting of previously granted awards.

On the same date, Feeley sold 369 shares of Class A Common Stock at $51.74 per share in an open-market transaction solely to cover tax withholding obligations from the RSU vesting, described as a “sell to cover” and not a discretionary trade. After these transactions, he beneficially owned 35,290 shares of Class A Common Stock, plus RSUs representing up to 91,702 additional shares and options to purchase up to 25,906 shares, all subject to their vesting schedules.

GeneDx Holdings Corp. received an updated Schedule 13D/A from investment groups associated with Eli Casdin and Keith Meister, detailing their ownership of the company’s Class A common stock. Based on 29,688,027 shares outstanding as of May 1, 2026, Eli Casdin reports beneficial ownership of 13.7% and Keith Meister reports 17.9%, including shares held through various funds, LLCs, warrants, options and restricted stock units. Corvex Management and Casdin Capital entities are also listed with double‑digit percentage stakes, reflecting significant institutional involvement in GeneDx.

GeneDx Holdings Corp. reported that investment entities associated with Casdin Capital made open-market purchases of a total of 500,000 shares of Class A Common Stock. These buys occurred on May 18–20, 2026 at weighted average prices in the low-to-mid $40 range.

After these transactions, an investment fund managed by Casdin Capital reported holding 3,507,164 shares indirectly. Separate positions include 20,517 shares owned directly by Eli Casdin and other indirect holdings of 333,144 and 19,247 shares reported for related entities.

GeneDx Holdings Corp. reported substantial insider-related buying of its Class A Common Stock by investment funds advised by Corvex Management LP. These funds purchased a total of 351,273 shares in open-market transactions between May 13 and May 15 at weighted average prices within ranges from about $37.78 to $40.60 per share.

After these transactions, the Corvex-advised funds directly hold 4,784,570 shares. In addition, CMLS Holdings LLC holds 333,144 shares, over which Keith A. Meister shares voting and investment discretion, and Meister separately holds 20,129 shares issued upon vesting of restricted stock units for his board service.

GeneDx Holdings Corp. insiders Eli Casdin and Keith Meister report updated ownership positions in this Schedule 13D amendment. Based on 29,688,027 Shares outstanding as of May 1, 2026, Eli Casdin beneficially owns 3,599,671 Shares, representing 12% of the Class A common stock. Keith Meister beneficially owns 5,356,767 Shares, representing 17.9% of the class. These stakes include Shares held through entities such as CMLS Holdings LLC, Casdin Partners Master Fund, LP and investment funds advised by Corvex Management LP. Certain holdings include 204,141 private placement warrants exercisable at $379.50 per Share, fully vested options and restricted stock units granted for board service. The filing notes that recent trades by the reporting persons were executed as open market transactions.